Pipeline
Investigational pipeline
Programs are presented for scientific and business-development purposes. Pipeline status reflects current development planning and may change.
| Program | Modality | Indication | Stage | Progress | Status |
|---|---|---|---|---|---|
| RNK001 | Allogeneic unmodified NK cell product | Ovarian cancer | Translational / clinical-development planning (Brazil) | DiscPrecTransClin | Investigational; subject to CMC, nonclinical, clinical, regulatory and ethics requirements |
| CAR-NK Ovarian | Engineered CAR-NK | Ovarian cancer | Preclinical / translational development | DiscPrecTransClin | Target selection and development path subject to regulatory gap assessment |
| NK / CAR-NK Expansion | NK or CAR-NK | Selected solid tumors and hematologic malignancies | Discovery / feasibility | DiscPrecTransClin | Indication selection and prioritization in progress |
Pipeline Disclaimer
Pipeline information is provided for scientific and business-development purposes only. BioNK investigational products are not approved for commercial use. Development status may change based on evidence generation, regulatory feedback, funding, manufacturing readiness, and governance decisions.